Skyrizi Dosing
SKYRIZI DEVICES
Skyrizi MOA
SKYRIZI DOSING

For Ps & For PsA

1 injection, 4 times a year

after week 0 and week 4 injections1

For Ps & For PsA

Reliable 3-MONTH DOSING1

ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION AT:

Initiation

SKYRIZI® dosing pen.

WEEK 0

SKYRIZI® dosing pen.

WEEK 4

Month 3

SKYRIZI® dosing pen.

WEEK 16

Month 6

SKYRIZI® dosing pen.

WEEK 28

Month 9

SKYRIZI® dosing pen.

WEEK 40

Month 12

SKYRIZI® dosing pen.

WEEK 52

FLEXIBILITY to choose between the 150 mg/mL single-dose pen
or 150 mg/mL single-dose prefilled syringe

The SKYRIZI Pen was awarded an Ease of Use certification from the Arthritis Foundation’s independent lab testing, which included patients with psoriatic arthritis.2

1 INJECTION,
4 TIMES A YEAR1

after 2 initiation doses
at Week 0 and Week 4

2 administration options1

for in-office or at-home administration after proper training

1 DOSAGE
FOR ALL PATIENTS1

regardless of baseline weight,
disease severity, or prior treatment

ADMINISTRATION Considerations

  • SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1
  • SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1
SKYRIZI® dosing card PDF.

Download OR EMAIL
DOSING CARD

Download or Email

Dosing Considerations

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1

SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.1

SKYRIZI® dosing card

Download OR EMAIL
DOSING CARD

Download or Email
Three women embracing

Considering SKYRIZI
for your patients?

See what coverage for SKYRIZI looks like.

VIEW ACCESS
Man in a blue swimsuit raises his hands in celebration

Already familiar
with SKYRIZI?

Find frequently used forms for your office.

VIEW RESOURCES

INJECTION SUPPORT VIDEOS

Video thumbnail for 150 mg/mL SKYRIZI pen video.

150 mg/mL
SKYRIZI PEN

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

Video thumbnail for SKYRIZI 150 mg/mL prefilled syringe video.

150 mg/mL
PREFILLED SYRINGE

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

WATCH VIDEO
EMAIL

Dosing Schedules

SKYRIZI is the only 4-dose-a-year biologic in psoriasis and psoriatic arthritis that offers a single-dose pen1

Ps DOSING Ps DOSING
PsA DOSING PsA DOSING

Ps DOSING SCHEDULES FOR SELECT BIOLOGICS FOR MODERATE TO SEVERE Ps1,3-8*

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

Ps dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

ILUMYA® (tildrakizumab-asmn)

Ps dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

Ps dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Taltz® (ixekizumab)

Ps dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

.

.

.

.

160 mg (two 80 mg injections) at Week 0 followed by 80 mg every 2 weeks through Week 12

COSENTYX® (secukinumab)

Ps dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

.

.

.

.

.

Once-weekly dosing for the first 5 doses

SILIQ® (brodalumab)

Ps Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation

.

.

.

Initiation doses at Weeks 0, 1, and 2

HUMIRA® (adalimumab)

Ps dosing: 80 mg subcutaneous injection at Week 0; 40 mg every other week starting 1 week after initiation

.

Initiation dose at Week 0

Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.

YEARLY DOSING† (AFTER INITIATION)

SKYRIZI® (risankizumab-rzaa)

Ps dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

ILUMYA® (tildrakizumab-asmn)

Ps dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

TREMFYA® (guselkumab)

Ps dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

Every 8 Weeks

Total of 6 doses a year

.

.

.

.

.

.

Taltz® (ixekizumab)

Ps dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

COSENTYX® (secukinumab)

Ps dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

SILIQ® (brodalumab)

Ps Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

.


.

.

.

.

.

.

.

.

.

.

.

HUMIRA® (adalimumab)

Ps dosing: 40 mg subcutaneous injection every other week

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.

PsA DOSING SCHEDULES FOR SELECT BIOLOGICS FOR ADULTS WITH ACTIVE PsA1,4-7*

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

PsA dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

PsA dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Taltz® (ixekizumab)

PsA recommended dosing: 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.

For patients with PsA and coexistent moderate-to-severe Ps, the dosing regimen for adult Ps should be used.

.

160 mg (two 80 mg injections) at Week 0

COSENTYX® (secukinumab)

PsA dosing: With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without a loading dosage: 150 mg every 4 weeks. If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks.

For patients with PsA and coexistent moderate to severe Ps, the dosing and administration recommendations for Ps should be used.

.

.

.

.

.

Option to dose once-weekly for the first 5 doses or not initiate doses

HUMIRA® (adalimumab)

PsA dosing: 40 mg subcutaneous injection every other week

 

No initiation dose required

Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.

MAINTENANCE DOSING† (AFTER INITIATION)

SKYRIZI® (risankizumab-rzaa)

PsA dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

 

TREMFYA® (guselkumab)

PsA dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

Every 8 Weeks

Total of 6 doses a year

.

.

.

.

.

.

 

Taltz® (ixekizumab)

PsA dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

 

COSENTYX® (secukinumab)

PsA dosing: With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without a loading dosage: 150 mg every 4 weeks

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

 

HUMIRA® (adalimumab)

PsA dosing: 40 mg subcutaneous injection every other week

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

 

Click to see HUMIRA® (adalimumab) Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy. See Full Prescribing Information.

INDICATIONS

SKYRIZI® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in adults.

ILUMYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.

Taltz® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.

COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.

SILIQ® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

HUMIRA® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis (Ps) and for adult patients with active psoriatic arthritis (PsA).

This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.1

Dosing schedules as of 1/25/2022.

 

*For IL-17is, IL-23is, and a TNF-alpha inhibitor.

†Based on doses required in each 48-week maintenance treatment period.

See Skyrizi Results in Ps

after 1 dose9

View patient case study

Enroll patients in SKYRIZI complete

Resources for your patients

Enroll Now

Dosing schedules FOR IL-17 and IL-23 INHIBITORS1-6

asfaf

asfaf

asfaf

asfaf

asfaf

asfaf

Dosing Schedules For IL-17 And IL-23 Inhibitors Dosing Schedules For IL-17 And IL-23 Inhibitors Dosing Schedules For IL-17 And IL-23 Inhibitors

This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.

*Based on doses required in each 48-week maintenance treatment period.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to inject 2 prefilled 75 mg syringes for the full 150 mg dose and to read the Instructions for Use before administration.